Role of the ubiquitin proteasome system in Parkinson's disease

Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Although a subject of intense research, the etiology of PD remains poorly understood. Recently, several lines of evidence have implicated an intimate link between aberrations in the ubiquitin proteasome system (UPS) and PD pathogenesis. Derangements of the UPS, which normally functions as a type of protein degradation machinery, lead to alterations in protein homeostasis that could conceivably promote the toxic accumulation of proteins detrimental to neuronal survival. Not surprisingly, various cellular and animal models of PD that are based on direct disruption of UPS function reproduce the most prominent features of PD. Although persuasive, new developments in the past few years have in fact raised serious questions about the link between the UPS and PD. Here I review current thoughts and controversies about their relationship and discuss whether strategies aimed at mitigating UPS dysfunction could represent rational ways to intervene in the disease.Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

[1]  V. Baekelandt,et al.  Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[3]  L. Pallanck,et al.  Parkin A Multipurpose Neuroprotective Agent? , 2003, Neuron.

[4]  A. Ciechanover,et al.  Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. , 1983, The Journal of biological chemistry.

[5]  A. Cuervo.  Autophagy in neurons: it is not all about food. , 2006, Trends in molecular medicine.

[6]  P. Kloetzel,et al.  The base of the proteasome regulatory particle exhibits chaperone-like activity , 1999, Nature Cell Biology.

[7]  Howard Riezman,et al.  Proteasome-Independent Functions of Ubiquitin in Endocytosis and Signaling , 2007, Science.

[8]  A. Goldberg,et al.  Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. , 2001, Molecular cell.

[9]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[10]  J. Kordower,et al.  Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys , 2006, Annals of neurology.

[11]  Zhijian J. Chen,et al.  TAK1 is a ubiquitin-dependent kinase of MKK and IKK , 2001, Nature.

[12]  P. Auluck,et al.  Mechanisms of Suppression of α-Synuclein Neurotoxicity by Geldanamycin in Drosophila* , 2005, Journal of Biological Chemistry.

[13]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[14]  L. Stefanis,et al.  Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up‐regulate iHSP70, following proteasomal inhibition , 2005, Journal of neurochemistry.

[15]  V. Calabrese,et al.  PROJECTED NUMBER OF PEOPLE WITH PARKINSON DISEASE IN THE MOST POPULOUS NATIONS, 2005 THROUGH 2030 , 2007, Neurology.

[16]  T. Dawson,et al.  Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate* , 2006, Journal of Biological Chemistry.

[17]  D. Perl,et al.  Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.

[18]  M. Cookson,et al.  Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin–proteasome system , 2006, Neurobiology of Disease.

[19]  D. Taillandier,et al.  Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles. , 2004, The Biochemical journal.

[20]  C. Ross,et al.  Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation , 2005, The Journal of Neuroscience.

[21]  J. Trojanowski,et al.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.

[22]  J. Gee,et al.  Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain. , 2004, The international journal of biochemistry & cell biology.

[23]  N. Déglon,et al.  Lentiviral-mediated RNA interference. , 2002, Human gene therapy.

[24]  Santiago Canals,et al.  Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. , 2003, Human molecular genetics.

[25]  Linda Hicke,et al.  Ubiquitin-binding domains , 2005, Nature Reviews Molecular Cell Biology.

[26]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[27]  D. Ecker,et al.  A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. , 1989, Science.

[28]  D. Rubinsztein,et al.  Lithium induces autophagy by inhibiting inositol monophosphatase , 2005, The Journal of cell biology.

[29]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[30]  K. Lim,et al.  Loss of locus coeruleus neurons and reduced startle in parkin null mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Olanow,et al.  Proteasome inhibitor–induced model of Parkinson's disease , 2006, Annals of neurology.

[32]  A. Członkowska,et al.  Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. , 2004, International immunopharmacology.

[33]  A. Brice,et al.  Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. , 2006, Human molecular genetics.

[34]  Jian Feng,et al.  Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. , 2004, Human molecular genetics.

[35]  A. Brice,et al.  A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K–Akt signalling , 2006, Nature Cell Biology.

[36]  S. Miyachi,et al.  Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates. , 2007, Neuroscience.

[37]  L. Forno,et al.  Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.

[38]  S. Miyachi,et al.  Neuronal specificity of α-synuclein toxicity and effect of Parkin co-expression in primates , 2007, Neuroscience.

[39]  R. Palmiter,et al.  Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age* , 2003, Journal of Biological Chemistry.

[40]  Li Chen,et al.  α-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains* , 2005, Journal of Biological Chemistry.

[41]  Olga Pletnikova,et al.  Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. , 2005, Human molecular genetics.

[42]  J. Feldon,et al.  DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in Mice. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  D. Rubinsztein,et al.  Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. , 2006, Current topics in developmental biology.

[44]  H. Miwa,et al.  Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition , 2005, Neuroscience Letters.

[45]  Takayuki Harada,et al.  Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice , 1999, Nature Genetics.

[46]  R. Haguenauer‐Tsapis,et al.  Ubiquitin Lys63 is involved in ubiquitination of a yeast plasma membrane protein , 1997, The EMBO journal.

[47]  Hongjun Song,et al.  Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death , 2005, The Journal of Neuroscience.

[48]  N. Wood,et al.  Molecular pathogenesis of Parkinson's disease. , 2005, Human molecular genetics.

[49]  K. Winklhofer,et al.  Inactivation of Parkin by Oxidative Stress and C-terminal Truncations , 2003, Journal of Biological Chemistry.

[50]  P. Jenner,et al.  Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats , 2006, Annals of neurology.

[51]  Masaaki Komatsu,et al.  Loss of autophagy in the central nervous system causes neurodegeneration in mice , 2006, Nature.

[52]  J. Brodsky,et al.  Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. , 2005, Molecular biology of the cell.

[53]  M. Yaffe,et al.  A Role for Ubiquitination in Mitochondrial Inheritance in Saccharomyces cerevisiae , 1999, The Journal of cell biology.

[54]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[55]  N. Wood,et al.  Genetic causes of Parkinson’s disease: UCHL-1 , 2004, Cell and Tissue Research.

[56]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Medhurst,et al.  Proteasomal activity in brain differs between species and brain regions and changes with age , 2005, Mechanisms of Ageing and Development.

[58]  J. C. Greene,et al.  Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  L. Dick,et al.  Kinetic characterization of the chymotryptic activity of the 20S proteasome. , 1996, Biochemistry.

[60]  Steven P Gygi,et al.  A proteomics approach to understanding protein ubiquitination , 2003, Nature Biotechnology.

[61]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[62]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[63]  P. Auluck,et al.  Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. , 2005, The Journal of biological chemistry.

[64]  T. Dawson,et al.  Diagnosis and treatment of Parkinson disease: molecules to medicine. , 2006, The Journal of clinical investigation.

[65]  A. Matouschek,et al.  Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.

[66]  Kiran Madura,et al.  Proteasome dysfunction in aged human α-synuclein transgenic mice , 2006, Neurobiology of Disease.

[67]  Jin Man Kim,et al.  Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Yamada,et al.  Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. , 2005, Human gene therapy.

[69]  Hitoshi Takahashi,et al.  An autopsy case of autosomal‐recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene , 2000, Movement disorders : official journal of the Movement Disorder Society.

[70]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[71]  W. Baumeister,et al.  A Subcomplex of the Proteasome Regulatory Particle Required for Ubiquitin-Conjugate Degradation and Related to the COP9-Signalosome and eIF3 , 1998, Cell.

[72]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[73]  P. Lockhart,et al.  RING finger 1 mutations in Parkin produce altered localization of the protein. , 2003, Human molecular genetics.

[74]  K. Lim,et al.  Molecular Mechanisms of Neurodegeneration in Parkinson's Disease: Clues from Mendelian Syndromes , 2003, IUBMB life.

[75]  Mark Guttman,et al.  Brain proteasomal function in sporadic Parkinson's disease and related disorders , 2002, Annals of neurology.

[76]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[77]  Bryan L Roth,et al.  Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[78]  A. Haas,et al.  A ubiquitin mutant with specific defects in DNA repair and multiubiquitination , 1995, Molecular and cellular biology.

[79]  J. Bronstein,et al.  Inhibitory effects of pesticides on proteasome activity: Implication in Parkinson's disease , 2006, Neurobiology of Disease.

[80]  L. Petrucelli,et al.  SEPT5_v2 is a parkin-binding protein. , 2003, Brain research. Molecular brain research.

[81]  K. Lim,et al.  Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease‐linked point mutations , 2005, Journal of neurochemistry.

[82]  Jeffrey N Keller,et al.  Proteasome Inhibition Alters Neural Mitochondrial Homeostasis and Mitochondria Turnover* , 2004, Journal of Biological Chemistry.

[83]  M. Ruberg,et al.  The C289G and C418R missense mutations cause rapid sequestration of human Parkin into insoluble aggregates , 2003, Neurobiology of Disease.

[84]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[85]  Takashi Uehara,et al.  Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[87]  A. Nanji,et al.  Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease. , 2004, Alcoholism, clinical and experimental research.

[88]  C. Olanow,et al.  Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures , 2002, Journal of neurochemistry.

[89]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[90]  Isao Nishimura,et al.  Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.

[91]  N. Thakor,et al.  Parkin Facilitates the Elimination of Expanded Polyglutamine Proteins and Leads to Preservation of Proteasome Function* , 2003, Journal of Biological Chemistry.

[92]  R. Palmiter,et al.  Parkin-deficient mice are not a robust model of parkinsonism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[93]  J. Cooper,et al.  Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons , 2006, Annals of neurology.

[94]  S. Tsuji,et al.  Familial juvenile parkinsonism , 1994, Neurology.

[95]  K. Lim,et al.  Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases? , 2006, Neurobiology of Aging.

[96]  G. Lazzeri,et al.  Fine Structure and Biochemical Mechanisms Underlying Nigrostriatal Inclusions and Cell Death after Proteasome Inhibition , 2003, The Journal of Neuroscience.

[97]  D. Selkoe,et al.  Dopamine covalently modifies and functionally inactivates parkin , 2005, Nature Medicine.

[98]  D. Rubinsztein,et al.  Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein* , 2007, Journal of Biological Chemistry.

[99]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[100]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[101]  B. Hyman,et al.  Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.

[102]  N. Hattori,et al.  Parkin attenuates manganese‐induced dopaminergic cell death , 2004, Journal of neurochemistry.

[103]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[104]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[105]  T. Kondo,et al.  Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q , 1998, Neurology.

[106]  A. Landau,et al.  Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle , 2007, Movement disorders : official journal of the Movement Disorder Society.

[107]  M. Ellison,et al.  Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain , 1994, Molecular and cellular biology.

[108]  Jochen Klucken,et al.  Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.

[109]  N. Hattori,et al.  Diverse Effects of Pathogenic Mutations of Parkin That Catalyze Multiple Monoubiquitylation in Vitro* , 2006, Journal of Biological Chemistry.

[110]  H. Lipp,et al.  Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[111]  Hideyuki Okano,et al.  Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice , 2006, Nature.

[112]  A. Abeliovich,et al.  Parkin Is a Component of an SCF-like Ubiquitin Ligase Complex and Protects Postmitotic Neurons from Kainate Excitotoxicity , 2003, Neuron.

[113]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[114]  J. Langston,et al.  Lack of nigrostriatal pathology in a rat model of proteasome inhibition , 2006, Annals of neurology.

[115]  Yumei Wang,et al.  Geldanamycin Induces Heat Shock Protein 70 and Protects against MPTP-induced Dopaminergic Neurotoxicity in Mice* , 2005, Journal of Biological Chemistry.

[116]  Vidya N. Nukala,et al.  Characterization of chronic low‐level proteasome inhibition on neural homeostasis , 2003, Journal of neurochemistry.

[117]  Y. Imai,et al.  Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity* , 2000, The Journal of Biological Chemistry.

[118]  B. Ghetti,et al.  Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.

[119]  B. E. Staveley,et al.  parkin counteracts symptoms in a Drosophila model of Parkinson's disease , 2004, BMC Neuroscience.

[120]  Jeffrey H Kordower,et al.  Proteasome inhibition and Parkinson's disease modeling , 2006, Annals of neurology.

[121]  J. Troncoso,et al.  S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.

[122]  Junying Yuan,et al.  Autophagy in cell death: an innocent convict? , 2005, The Journal of clinical investigation.

[123]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[124]  A. Lang,et al.  The proteasomal inhibition model of Parkinson's disease: “Boon or bust”? , 2006, Annals of neurology.